anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Habitual sleep duration varies greatly among individuals. The biological meaning of this variation is unknown. The present project proposes that differences in habitual sleep duration are associated with differences in the output of the endogenous circadian pacemaker, which programs the 'internal biological night'. The protocol hypothesizes that the duration of the internal biological night as defined by the nocturnal intervals of detectable plasma melatonin levels, low body temperature, low EEG activity in the high-frequency alpha band, increasing sleepiness and increasing plasma cortisol levels is longer in habitual long sleepers (sleep duration greater than 9 hours) than in short sleepers (less than 6 hours). Since recent results in healthy subjects suggest that melatonin has some soporific or hypnotic properties, we furthermore hypothesize that the level of nocturnal melatonin secretion is higher in long sleepers than in short sleepers. The circadian rhythms of plasma melatonin, body temperature, waking EEG activity, subjective sleepiness and plasma cortisol will be assessed in a \~40-hour constant routine protocol. In addition, a 36-hour extended bed rest protocol will be carried out in order to study spontaneous sleep duration and sleep structure under ad lib conditions while time cues and social cues are absent. It is hypothesized that as a consequence of differences in the circadian output, long sleepers will sleep more, have a different sleep structure, and spontaneously wake up on a lower level of homeostatic sleep pressure than short sleepers. Finally, we intend to determine whether differences in habitual sleep duration between long and short sleepers are associated with dysthymic and hypomanic characteristics of mood, respectively. We are asking to study a total of 15 long sleepers and 15 short sleepers. Given that we have already studied 9 long sleepers and 9 short sleepers, we anticipate that 72 patient-days per year for one year would be required to complete the study.
Risk Summary

There are no available data on Halobetasol Propionate Topical Foam use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Published data report an increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. In animal reproduction studies, increased malformations, including cleft palate and omphalocele, were observed after oral administration of halobetasol propionate during organogenesis to pregnant rats and rabbits. No comparisons of animal exposure with human exposure may be calculated due to minimal systemic exposure in humans after topical administration of Halobetasol Propionate Topical Foam [see Clinical Pharmacology (12.3)]. The background risk of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Human Data

Multiple observational studies found no significant associations between maternal use of topical corticosteroids of any potency and congenital malformations, preterm delivery, or fetal mortality. However, when the dispensed amount of potent or very potent topical corticosteroid exceeded 300 g during the entire pregnancy, use was associated with an increase in low birth weight infants.

Animal Data

Halobetasol propionate has been shown to cause malformations in rats and rabbits when given orally during organogenesis at doses of 0.04 to 0.1 mg/kg/day in rats and 0.01 mg/kg/day in rabbits. Halobetasol propionate was embryotoxic in rabbits, but not in rats. Cleft palate was observed in both rats and rabbits. Omphalocele was seen in rats, but not in rabbits.
Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
In the present invention, there are disclosed thienylazolylalkoxyethanamines of the general formula I in which R1 represents a hydrogen atom, a halogen atom or a lower alkyl group; R2, R3 and R4 represent, independently on each other, a hydrogen atom or a lower alkyl group; and Az represents a five-membered N-methyl-substituted nitrogenous heterocyclic aromatic ring containing from one to three nitrogen atoms. These compounds exhibit analgesic activity in mammals, including humans. The compounds of the general formula I can be obtained, for example, by reacting hydroxy-thienyl azole IV with a derivative of a suitable N-ethylamine. The compounds of the general formula IV are useful intermediates in the synthesis of the compounds of the general formula I. The compounds of the general formula I have an application in human and/or veterinary medicine. The invention also relates to a pharmaceutical composition in which the compound of the general formula I is comprised.
PURPOSE:To provide a new indenestrol derivative giving excellent proliferation- suppressive activity on oncocytes, thus useful as an antineoplastic agent. CONSTITUTION:The indenestrol derivative of formula I or II (R<1> and R are each H or 1-5C alkyl, however, excepting the case where they are H or alkyl at the same time), e.g. (-)-(S)-6-o-methylindenestrol A of formula III. The compound of the formula I or II can be obtained by alkylating one of the hydroxyl groups in dienestrol to form a dienestrol monoalkyl ether, which is then put to ring opening reaction. The compound of the formula I or II can be safely administered orally or parenterally as a medicine, its effective dose a day per adult being pref. 0.01-80mg per kg bw for injection, while 0.5-120mg in one to several portions for oral administration.
PURPOSE:To stabilize an insolubilized protein for a long time by a simple process, by immobilizing a protein on an insoluble carrier followed by treating with a magnesium sulfate solution. CONSTITUTION:A protein (e.g. a cancer-associated antigen or a hydrolytic enzyme) is made to be adsorbed physically or immobilized using glutar-aldehyde, etc. as a crosslinker on an insoluble carrier (e.g. a sheet, a tube or beads of polystyrene, polyacrylate or paper). The insolubilized protein thus obtained is dipped in a magnesium sulfate solution with a concentration of about 0.005-1 M and dried overnight. In the dipping treatment above-mentioned, an inactive protein (e.g. bovine serum albumin or bovine gamma-globulin) may also be contained in the solution.
PURPOSE:To obtain a 5-fluorouridine derivative useful for a medicine composition having carcinostatic activity industrially and advantageously by treating a strain of a bacterium which belongs to the genus Serrate or an enzyme in its cell with 5-fluorouridine in the presence of a phosphate group supplying source. CONSTITUTION:A strain of a bacterium (e.g. Serratia.marcescens IFO3046) which belongs to the genus Serratia or an enzyme in its cell is brought into contact with 5-fluorouridine of formula I in the presence of galactose and a phosphate group supplying source (e.g. p-nitrophenylphosphoric acid) and is reacted in an aqueous medium at 47 deg.C for 24 hours while slowly shaking and the cell is removed by centrifuging. The supernatant liquid is adjusted to pH3.8 and treated with active carbon. The adsorbed substance is eluted with ethanol : ammonia water : water (50:5:45). The eluate is treated with an adsorbing resin, the adsorbed substance is eluted and purified to give the objective 5- fluorouridine-5'-phosphate of formula II ester useful as a medicine composition having carcinostatic activity.
The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and agonize EphA4. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that preferentially binds to an EphA4 epitope that is exposed on cancer cells but not non-cancer cells. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 with a very low K off  to reduce EphA4 expression and, thereby, inhibit tumor cell growth and/or metastasis. The invention also provides pharmaceutical compositions comprising one or more EphA4 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
Dynamic balance exercises: The treatment will be performed in 3 days a week for 6 weeks. Each exercise will last 30 minutes. It will take 18 sessions in total. These exercises include 14 balance exercise movements performed on tecnobody prokin 252 balance device.
A prospective, randomized clinical trial was performed on 28 patients (22 females, 6 males) with an average age of 65 years (range, 53 to 77) undergoing complete arthroscopic repair of a massive rotator cuff tear. In 14 patients, after the repair was completed, 6 cc. of PRF (vivostat ®) were locally applied to the repair site. In 14 patients no addition of PRF was performed. All patients underwent an arthro-MRI to evaluate the integrity of the repair and a clinical exam one year after the operation. All patients were then followed clinically at a minimum of 2 years. Functional outcome was evaluated with the Constant and DASH scores.
The invention discloses a Chinese patent medicine and a Chinese decoction capable of effectively treating diabetes. According to a Chinese medicinal formula, the Chinese patent medicine is characterized by comprising the following medicinal materials by weight: 40 g of flower of Chinese scholartree, 20 g of radix trichosanthis, 15 g of kudzu root, 20 g of picrorhiza rhizome, 20 g of kuh-seng, 15 g of bark of amur corktree, 25 g of rhizoma anemarrhenae, 20 g of atractylodes macrocephala and 20 g of yam. The invention has the advantages that: the formula for treating diabetes belongs to a folk prescription for treating diabetes. The good healing effect of the Chinese decoction on the diabetes is proved. At present, the number of people suffering from diabetes is growing all over the world, so that effective treatment of diabetes becomes an urgent affair. The Chinese medicinal folk prescription can be further used for preparing pills, powder, particles, tablets, capsules and the like of the Chinese patent medicine, which can bring the advantages of the Chinese patent medicine into play, are readily available, adapt to urgent demands, are convenient to store, and can be taken along. The Chinese patent medicine and the Chinese decoction capable of effectively treating diabetes have extremely great commercial development prospects, and bring good news for a large number of patients suffering from diabetes.
The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days. At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
INTRODUCTION: Infertility is one of the important phenomena in human reproduction. Genetic factors are the most important cause of male infertility. Here, we aimed to investigate the correlation between idiopathic male infertility and SNPs of the LHCGR (rs2293275) and NR5A1 (rs1057517779) genes in the Iranian-Azeri population.
METHODS: This case-control study consisted of 100 males with infertility and 100 healthy males from the Iranian Azeri population. Genomic DNA isolation from whole blood samples and Tetra-primer amplification refractory mutation system-polymerase chain reaction (Tetra-ARMS-PCR) method was used for genotyping. The data analysis was performed by chi-square (χ2) and Fisher's exact tests.
RESULTS: Genotyping analysis for LHCGR (rs2293275) polymorphism indicated that the frequency of C in the case group was significantly higher than in the control group (P < .05). Moreover, genotyping analysis for NR5A1 (rs1057517779) polymorphism indicated that the frequencies of the A allele and heterozygote GA genotype in the case group were significantly higher than those in the control group (P < .05).
CONCLUSION: Our study demonstrated that the SNPs of LHCGR (rs2293275) and NR5A1 (rs1057517779) genes may play a critical role in male infertility in the Iranian Azeri population. However, further studies on other ethnic origins with larger sample sizes are essential for accessing more accurate results. Moreover, functional experiments might be needed to understand the role of these polymorphisms in the molecular pathways involved in male fertility.
Advise patients to read the FDA-approved patient labeling (Patient Information).

Pregnancy:Advise female patients of childbearing age about the consequences of exposure to ENTRESTO during pregnancy. Discuss treatment options with women planning to become pregnant. Ask patients to report pregnancies to their physicians as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. 

Angioedema:Advise patients to discontinue use of their previous ACE inhibitor or ARB. Advise patients to allow a 36 hour wash-out period if switching from or to an ACE inhibitor [see Contraindications (4)and Warnings and Precautions (5.2)]. 

T2021-08
Light sedation will started when the patient admitted to ICU after non-cardiac surgery under general anaesthesia with dexmedetomidine, which was continuously intravenously pumped at a rate of 0.2-0.7ug/kg/h. Depth of sedation will assessed by RASS score hourly to ensure a RASS score of 0 to -3. At the same time, use remifentanil (0.1-0.5/kg/min) as a combination analgesic drug to ensure that the CPOT is less than or equal to 2 points. When a satisfactory level of RASS score (0 to -3 points) was still not achieved within the dose range, a remedial programme of sedation will started using propofol.During the ICU stay, daily sedation interruption and spontaneous breathing test will be performed. If successful, sedation will be terminated, followed by weaning and extubation. If unsuccessful, mechanical ventilation will continue.
Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Objective: Ankylosing Spondylitis (AS) is a chronic, inflammatory rheumatic disease that effects primarily axial-spine. With progression of disease, flexibility of thorax and spine will be get lost. It is reported that mobility, function, respiratory muscle strength and endurance get worse in AS patients. Reduction of flexibility and mobility is important factors that can cause muscle weakness, impairment quality of life, reduction of exercise tolerance and pulmonary capacity with the progression of AS. To writer's knowledge, there has been no study examining the effects of pilates exercises on mobility, function and respiratory muscle strength in AS patients. The purpose of this study is to investigate the effects of pilates exercises on mobility, function and respiratory muscle strength in patients with AS.

Methods: Forty patients were included who are aged between 18-65 years and got diagnosed according to Modified New York criterias. Patients who have incooperation, malignancy and pregnancy will be excluded from the study. Patients will be divided into two groups randomly. Pilates training will be performed to the treatment group and conventional exercises will be performed to the control group during 8 weeks Respiratory muscle strength will be assessed by maximal inspiratory and expiratory pressures. Thorax expansion will be measured from regions of axillar, subcostal and epigastric by tape measure. To evaluate disease activity and spinal mobility, we will use Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Metrology Index (BASMI), respectively. Quality of life will be evaluated with Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL). Exercise capacity will be assessed by 6 minutes walk test. Pilates exercises will be performed 3 days in a week for 8 weeks. Conventional exercise programme will be taugt to the control group and requested to perform them at home. The assessments will be repeated in before and after treatment.
All procedures will be performed by the advance endoscopists Dr Sumant Inamdar (SI) and Dr Benjamin Tharian (BT) using a linear array echoendoscope (Olympus UCT180, Olympus America Corp, Center Valley, Pa) with patients in the left lateral decubitus position after administration of anesthesia (propofol or general anesthesia). During EUS, the mass will first be punctured using either needle based on the randomization assignment. Tissue acquisition will be performed using the fanning maneuver (4 strokes at 4 different locations within the mass). After performing 2 dedicated passes for cell block for histological analysis using the randomized needle, 2 additional passes will be made for cell block with the alternate needle. Sample obtained from each pass is placed into a separate container to be analysed separately. The occurrence of immediate adverse events will be noted at the time of procedure, and late adverse events will be documented by follow-up telephone calls at 1 week post-procedure
Filicide is the act of a parent killing their own offspring. Previous studies indicate that there are both commonalities and distinctions between filicides committed by mothers and fathers. The main objective of this study was to compare maternal and paternal filicide with a major focus on clinical and sociodemographic features of perpetrators, incident details, and victims. Filicide cases were examined at the bedded unit of the Expertise Department of Observation of the Council of Forensic Medicine that were referred by the Turkish Ministry of Justice. A total of 51 perpetrators and 57 victims were analyzed from June 2014 to December 2023. The perpetrators were daily face-to-face interviewed by psychiatry and forensic medicine physicians. There were significant differences in sociodemographic characteristics and psychiatric conditions between maternal and paternal cases. Female perpetrators tended to be younger, unemployed, mostly targeted younger victims and used asphyxiation to kill, whereas males tended to target older victims and utilized firearms. The most common primary cause of filicide in maternal cases was "unwanted pregnancy," whereas "spousal revenge" and "anger or impulsivity" were predominant in paternal filicides. All perpetrators who were not criminally responsible were mothers, mostly diagnosed with psychotic depression. Unwanted pregnancy, psychotic depression, and postpartum psychosis should be assessed when evaluating risk for mothers, especially for infanticide. The desire for revenge on a spouse, often seen with personality disorders, impulsivity and anger, access to firearms should be screened for risk of paternal filicide, particularly in older victims. Early recognition of these factors can help in implementing prevention strategies.
Patients receive 3 courses of preoperative neoadjuvant chemotherapy given on day 1 every 21 days. Courses consist of an intravenous infusion of cisplatin and a 3 hour intravenous infusion of paclitaxel on day 1. Patients then undergo surgery for tumor removal on day 63, followed 4-6 weeks later by one course of daily intravenous bolus leucovorin calcium and fluorouracil for 5 days. Chemotherapy is repeated 4-6 weeks later for the first 4 days of week 1 and the last 3 days of week 5 of radiation therapy given 5 days a week for 5 weeks. Patients receive two more courses, 4 weeks apart, of fluorouracil and leucovorin calcium for 5 days 4-6 weeks after completing radiation treatment.
Our primary aim is to study the perioperative hemodynamic profile of patients on chronic steroids undergoing colon and rectal surgery. We will do this by measuring heart rate, temperature and blood pressure in the operating room and during their postoperative hospitalization. Patients will be identified in their preoperative visit. They will be randomized to high dose and low dose steroid study groups. The standard dose steroid patients will receive hydrocortisone 100 mg IV preoperatively and 100 mg IV every 8 hrs with standard taper. The low dose steroid study group will receive the IV equivalent of their preoperative steroid dose in the postoperative period. The patients blood pressure, temperature and heart rate will be monitored in the operating room and the ward postoperatively. Outcomes will be compared between the two groups. We hypothesize that there will be no statistically significant difference in blood pressure, temperature or heart rate in the high dose and low dose groups.

The secondary aim of this study will be monitoring of any differences in surgical outcomes, including postoperative length of stay, between the two patient groups.
The invention provides an interferon-albumin nanometer aggregated particle with a hollow structure, and the preparation form is a dry powder inhalant. The particle is circular and integrated, the surface has recesses, the particle has a hollow spherical shell structure, the aerodynamic radius is 3.47 mu m, and the fine particles fraction (FPF) is 83.7%. The preparation has certain advantages on aspects of keeping interferon medicine activity, reducing administration dosage, reducing side effect and the like, and is a novel interferon dry powder inhalant possessing prospect. A preparation technology of the particle comprises employing an adsorption method and a wrapping carrying method to prepare an interferon-albumin nanometer solution, and then using a spraying drying technology to prepare the nanometer aggregated particle. The employed carrier is lactose. The optimum technology parameters comprise that the inlet temperature is 130 DEG C, the peristaltic-pump rotating speed is 5, the compressed-air pressure is 0.6 MPa, and the spraying-solution solid content is 3%.
Chronic myeloid leukemia (CML) is an oncological myeloproliferative disorder that accounts for 15 to 20% of all adult leukemia cases. The molecular basis of this disease lies in the formation of a chimeric oncogene BCR-ABL1. The protein product of this gene, p210 BCR-ABL1, exhibits abnormally high constitutive tyrosine kinase activity. Over recent decades, several targeted tyrosine kinase inhibitors (TKIs) directed against BCR-ABL1 have been developed and introduced into clinical practice. These inhibitors suppress BCR-ABL1 activity through various mechanisms. Furthermore, the advent of RNA interference technology has enabled the highly specific inhibition of BCR-ABL1 transcript expression using small interfering RNA (siRNA). This experimental evidence opens avenues for the development of a novel therapeutic strategy for CML, termed siRNA therapy. The review delves into molecular genetic mechanisms underlying the pathogenesis of CML, challenges in CML therapy, potential molecular targets for drug development, and the latest results from the application of siRNAs in in vitro and in vivo CML models.